Related references
Note: Only part of the references are listed.Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status
June Kaplow et al.
ALZHEIMERS & DEMENTIA (2020)
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays
Sebastien Boulo et al.
ALZHEIMERS & DEMENTIA (2020)
Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform
Constance Delaby et al.
CLINICA CHIMICA ACTA (2019)
Advantages and disadvantages of the use of the CSF Amyloid (A) 42/40 ratio in the diagnosis of Alzheimer's Disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Comparative evaluation of two immunoassays for cerebrospinal fluid β-Arnyloid1-42 measurement
Chiara Zecca et al.
CLINICA CHIMICA ACTA (2019)
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis
Silvia Paciotti et al.
CLINICA CHIMICA ACTA (2019)
Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis
Jean-Louis Bayart et al.
JOURNAL OF NEUROLOGY (2019)
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Daniel Alcolea et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study
Christopher A. Lane et al.
LANCET NEUROLOGY (2019)
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease
Maria Joao Leitao et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1-42 Peptide in the CSF
Alexander L. Kollhoff et al.
FRONTIERS IN AGING NEUROSCIENCE (2018)
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Leslie M. Shaw et al.
ALZHEIMERS & DEMENTIA (2018)
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
Shorena Janelidze et al.
JAMA NEUROLOGY (2017)
Study protocol: Insight 46-a neuroscience sub-study of the MRC National Survey of Health and Development
Christopher A. Lane et al.
BMC NEUROLOGY (2017)
Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
Sebastian Palmqvist et al.
BRAIN (2016)
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Shorena Janelidze et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Keith A. Johnson et al.
ALZHEIMERS & DEMENTIA (2013)
Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels
Sylvie Slaets et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Development and Advanced Validation of an Optimized Method for the Quantitation of Aβ42 in Human Cerebrospinal Fluid
Valerie C. Cullen et al.
AAPS JOURNAL (2012)
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study (vol 11, pg 669, 2012)
C. M. Clark et al.
LANCET NEUROLOGY (2012)
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark et al.
LANCET NEUROLOGY (2012)
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson et al.
ALZHEIMERS & DEMENTIA (2011)
Decreased Cerebrospinal Fluid Aβ42 Correlates with Brain Atrophy in Cognitively Normal Elderly
Anne M. Fagan et al.
ANNALS OF NEUROLOGY (2009)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds
I Skoog et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2003)
Share Paper
